论文部分内容阅读
目的:对冻干重组人脑利钠肽治疗难治性心力衰竭的临床效果进行分析和观察。方法:将2015年1月~2016年12月40例难治性心力衰竭患者,随机分为观察组和对照组,观察组接受冻干重组人脑利钠肽治疗,对照组接受硝普钠治疗,比较两组临床疗效。结果:两组患者不良反应总发生率均为20%(P>0.05);观察组LVEF、SV等心功能指标值显著优于对照组患者(P<0.05),治疗总有效率显著高于对照组患者(100%vs 60.00%)(P<0.05)。结论:冻干重组人脑利钠肽治疗难治性心力衰竭效果显著、安全可靠,可推荐使用。
Objective: To analyze and observe the clinical effect of freeze-dried recombinant human brain natriuretic peptide in the treatment of refractory heart failure. Methods: From January 2015 to December 2016, 40 patients with refractory heart failure were randomly divided into observation group and control group. The observation group received freeze-dried recombinant human brain natriuretic peptide and the control group received sodium nitroprusside , The clinical efficacy of two groups were compared. Results: The total incidence of adverse reactions in both groups was 20% (P> 0.05). The cardiac function indexes of LVEF and SV in the observation group were significantly better than those in the control group (P <0.05), and the total effective rate was significantly higher than that of the control Group patients (100% vs 60.00%) (P <0.05). Conclusion: Lyophilized recombinant human brain natriuretic peptide is effective and can be recommended for refractory heart failure.